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BACKGROUND  
• Microteaching effective for providing targeted 
education.
• Essential to have updates to electronic health 
records to track patient outcomes.
• Immunotherapy charting in ED augmented 
through paper & pencil form.








• The purpose of this project is to determine the 
effectiveness of microteaching on identification 
and treatment of IrAEs.
• Sub aims were to:
• measure immediate knowledge changes 
related to identification and management of 
IrAEs. 
• determine whether patient outcomes related 
to IrAEs were handled appropriately following 
education.
• Design:
• IRB approved descriptive, correlational study
• Patient outcomes from retrospective EHR 
review
• Sample: ED RNs and physicians
• Setting: SJO Emergency Care Center
• Procedure: 
• Knowledge pretest/posttest with tailored, 
micro-education delivered in small groups
• Retrospective EHR review to determine 
timeliness & appropriateness of treatment
• All ECC RN results demonstrated significant 
increases between pretest/posttest scores.
• Number of IrAEs identified by RNs:
• pretest = 0.52
• posttest = 3.77
• Physician education demonstrated increased 
knowledge post-education; two items reached 
statistical significance. 
• Retrospective EHR review:
• unique identifier for immunotherapy missing 
from EHR
• small numbers of ED patients with incomplete 
data
• When you hear hoofbeats think of horses, not 
zebras (Woodward, 1940).
• Increasing use of immunotherapy/checkpoint 
inhibitors (CI) as a single treatment or combined 
with chemotherapy.
• Immunotherapy adverse events (IrAEs) have 
unique presentations:
• often overlooked or misdiagnosed.
• auto-immune like reaction (Davies, 2016; Mistry et al., 
2017).
• Treatment for IrAEs requires high dose steroids 
(Davies, 2016; Mistry et al., 2017).
• It is essential for emergency department staff to 
have knowledge of & promptly identify patients 
with IrAEs (Davies, 2016).
• Non-oncology providers will increasingly 
encounter patients on immunotherapy.
• Microteaching effective in increasing knowledge 
of IrAEs and their treatment.
• EHR provides opportunities & challenges for 
retrieving outcome data for research, EBP, & QI 
projects.






Yes No Yes No P
Are you familiar with 
Immunotherapy as a treatment 
for cancer?
49.3% (36) 50.7% (37) 100% (71) (0) <.0001
Are you familiar with national 
guidelines for the management 
of immunotherapy adverse 
events?
2.7% (2) 97.3% (71) 97.2% (69) 2.8% (2) <.0001
Are you familiar with the 
intervention(s) needed to start 
reversing most immunotherapy 
adverse events?
6.8% (5) 93.2% (68) 100% (71) 0% (0) <.0001
True False True False
Immunotherapy and 
chemotherapy may be 
administered simultaneously.
50.7% (36) 49.3% (37) 88.7%% 
(63)
11.3% (8) <.0001
Neutropenic patients who are 
receiving chemotherapy can be 
treated with steroids.
42.5% (31) 57.6% (42) 95.8% (68) 4.3% (3) <.0001
Note. Phi co-efficients used to determine differences.
